Home / Market News / $EVO

$EVO news and market catalysts

The 8 most recent market catalysts affecting $EVO, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

8 catalysts 2 high impact 2 bullish 3 bearish Gambling/Gaming
Nov 19, 2026 Corporate Catalyst Bearish Impact 65
Evolution Settles with Law Firm Over Playtech-Funded Report
Evolution has reached a settlement with Calcagni & Kanefsky LLP, a law firm that was a defendant in a defamation lawsuit. This lawsuit stemmed from a 2021 report, funded by Playtec…
Nov 19, 2026 Corporate Catalyst Bullish Impact 65
Evotec and Bristol Myers Squibb Receive Second IND Acceptance for Protein Degradation Candidate
Evotec and Bristol Myers Squibb announced FDA acceptance for a second investigational new drug (IND) candidate, a cereblon E3 ligase modulator, under their strategic protein degrad…
Nov 6, 2026 Corporate Catalyst Neutral Impact 55
Evommune Announces Webcast to Discuss EVO570 and Immunology Pipeline
Evommune announced a webcast to discuss EVO570, an orally administered molecular glue degrader targeting VAV1, for which it holds ex-Greater China rights. This event is a routine c…
Oct 27, 2026 Corporate Catalyst Bullish Impact 55
Morgan Stanley Raises Price Target on Evolution AB
Morgan Stanley analyst Ed Young raised the price target for Evolution AB (EVO) shares from SEK 740 to SEK 780. This indicates a slightly more favorable valuation assessment by the …
Oct 14, 2026 Corporate Catalyst Neutral Impact 55
HC Wainwright & Co. Reiterates Buy on Evotec, Maintains $4 Price Target
This 8-K filing discloses that HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a 'Buy' rating on Evotec (EVO) and maintained a $4 price target. This is a routine …
Aug 13, 2026 Corporate Catalyst Bearish Impact 95
Evotec Q2 EPS $(0.15) Misses $(0.06) Estimate, Sales $166.802M Miss $212.370M Estimate
Evotec's Q2 earnings per share of $(0.15) missed the $(0.06) estimate by 150%, and sales of $166.802 million missed the $212.370 million estimate by 21.46%. This dual miss, especia…
Jul 15, 2026 Corporate Catalyst Bearish Impact 75
Evotec shares are trading lower after HC Wainright & Co lowered its price target on the stock from $7 to $4.
The downgrade of Evotec's price target from $7 to $4 by HC Wainright & Co is a significant negative catalyst for the stock. This substantial reduction, representing a nearly 43% cu…
Jul 13, 2026 Corporate Catalyst Neutral Impact 95
Evotec Now Expects FY26 Revenue From €700M - €780M To ~€570M - €610M, Expects H1 Revenue Of ~€300.1M
Evotec announced preliminary unaudited financial results for H1 2026 and a drastically revised full-year 2026 outlook. The company now expects FY26 revenues of €570M-€610M, down fr…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.